



Universal Influenza Vaccine Company Vivaldi Biosciences and BlueSky Vaccines Form Agreement on High Growth Influenza Strain Technology

– Vivaldi’s DeltaFLU Addresses Goals of President’s Executive Order on Modernizing Influenza Vaccines –

FORT COLLINS, Colorado and VIENNA, Austria – October 15, 2019 – Vivaldi Biosciences Inc., a clinical-stage company developing the DeltaFLU universal influenza vaccine, has signed a technology co-ownership agreement with BlueSky Vaccines GmbH, a Vienna company developing immunotherapies against cancer. The agreement covers US and European patent applications relating to high growth influenza virus strain technology. The jointly filed patent applications result from a successful collaboration between the two companies to genetically engineer influenza viruses for development of vaccines and immunotherapies. The agreement grants Vivaldi the exclusive right to develop and commercialize the technology in the field of infectious diseases.

Vivaldi is applying the technology to optimize production of its DeltaFLU universal influenza vaccine in Vero cell culture. Vivaldi has developed high growth DeltaFLU vaccine strains and an efficient Vero cell production system that in combination allow production of the finished DeltaFLU vaccine product within just seven weeks. Most licensed influenza vaccines are produced in eggs, which can take up to six months.

Vivaldi’s DeltaFLU universal influenza vaccine is a self-adjuvanting vaccine administered by nasal spray. DeltaFLU rapidly generates a robust immune response in the nasal passages, inducing interferon (a key component of the immune response to viral infection) and antibodies with neutralizing activity against a broad range of influenza virus subtypes. DeltaFLU also establishes broad and long-lasting protection through activation of T cells and systemic antibodies.

With demonstrated potential for superior efficacy and broad protection, advanced cell-based manufacturing, and needle-free administration, DeltaFLU satisfies key objectives of the recent Presidential Executive Order titled “Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health.” Specifically, DeltaFLU addresses urgent needs for: a broadly protective influenza vaccine that provides more effective and longer lasting immunity, reducing reliance on egg-based influenza vaccine production with a faster and more scalable manufacturing platform, and a delivery system that does not rely on needles and syringes, and enables rapid and large-scale administration of pandemic vaccines.

About DeltaFLU

Vivaldi Biosciences is developing DeltaFLU for intranasal administration, to provide broad protection and superior efficacy in the prophylaxis of seasonal and pandemic influenza. DeltaFLU is composed of influenza vaccine strains genetically modified by deletion of the gene for nonstructural protein 1 (NS1). Deletion of NS1 confers the unique and broadly protective mechanism of action of DeltaFLU and ensures the vaccine is safely attenuated. Lacking the ability to produce NS1, DeltaFLU rapidly induces interferon and broadly neutralizing antibodies in the nasal passages, creating a first line of defense directly at the point of entry of circulating viruses. The self-adjuvanting effect of interferon also creates a second line of

defense by stimulating the immune system's T cells and antibody-producing B cells to achieve a broadly protective systemic immune response. DeltaFLU vaccines have been evaluated successfully in four Phase 1 and Phase 2 clinical trials involving a total of 245 volunteers. The clinical trials demonstrate the potential for superior efficacy and broad protection against influenza A and B strains with a single dose. These studies also confirm that DeltaFLU vaccine strains are replication-deficient and are not shed by the recipient, providing significant safety advantages. In a nonclinical study, a single dose of DeltaFLU protected against widely drifted influenza A and B strains and even protected against a shifted influenza A strain.

About Vivaldi Biosciences

Vivaldi Biosciences is based at the Research Innovation Center at Colorado State University and in Vienna, Austria. NGN Capital LLC is the lead investor in Vivaldi Biosciences. Additional information can be found at www.vivaldibiosciences.com.

Contact:

Bill Wick, CEO, Vivaldi Biosciences

Tel: +1 650-400-8915

bill.wick@vivaldibiosciences.com

Forward-Looking Statements

This release contains forward-looking statements relating to Vivaldi Biosciences, which are not historical facts and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this communication concerning activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are based on current expectations and projections about future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, the following: the uncertainty of clinical success and of obtaining regulatory approvals, the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, product efficacy or safety concerns resulting in product recalls or regulatory action, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the ability to obtain future funding and to obtain such funding on commercially reasonable terms, the regulatory environment and other risks the Company may identify from time to time in the future. These factors are not necessarily all of the important factors that could cause our actual results, performance or achievements to differ materially from those expressed in or implied by any of our forward-looking statements. These forward-looking statements speak only as of the date of this communication and we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. This press release should not constitute an offer to sell or a solicitation of an offer to buy securities.